#SGOAM26
LightNews LightNews
medpagetoday.com
Almost 100% of patients with recurrent/metastatic endometrial cancer benefited from an investigational bispecific antibody plus standard chemotherapy, according to a small preliminary study from China. #SGOAM26 https://www.medpagetoday.com/meetingcoverage/sgo/120762
Near-Perfect Disease Control for Bispecific in Advanced Endometrial Cancer
Only one of 41 patients did not have at least stable disease with cadonilimab plus chemotherapy
www.medpagetoday.com
April 14, 2026 at 12:16 AM
onclive.bsky.social
Megan Hutchcraft, MD, dropped by for an interview to discuss how fellows can put themselves on the map in gyn onc social media! Check out onclive.com for clips from the interview.
#SGOAM26 #Oncology
April 11, 2026 at 10:05 PM
onclive.bsky.social
Thank you to Roisin O’Cearbhaill, MD, of @mskcancercenter.bsky.social for stopping by to discuss a phase 1/2 study of REGN5668 in patients with recurrent ovarian or endometrial cancer! Check out clips from the conversation on onclive.com #SGOAM26 #gynsm #Oncology
April 11, 2026 at 9:35 PM
medpagetoday.com
The investigational antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab (Keytruda) demonstrated encouraging antitumor activity in patients with recurrent or metastatic cervical cancer, according to phase II data. #SGOAM26
https://www.medpagetoday.com/meetingcoverage/sgo/120780
'Amazing' Results With Drug Combo in Metastatic Cervical Cancer
Combination with investigational antibody-drug conjugate showed encouraging antitumor activity
www.medpagetoday.com
April 14, 2026 at 7:40 PM
medpagetoday.com
A chemotherapy-free regimen for advanced/recurrent endometrial cancer achieved durable disease control in a substantial portion of patients, according to a study reported at #SGOAM26.
www.medpagetoday.com/meetingcover...
Chemo-Free Regimen for Endometrial Cancer Produces Durable Responses, Favorable PFS
More than half of patients with recurrent/advanced disease were progression-free at 6 months
www.medpagetoday.com
April 14, 2026 at 3:07 PM
onclive.bsky.social
🔬 New data from #SGOAM26: The ADC trastuzumab pamirtecan hit a ~50% response rate in pretreated HER2-expressing endometrial cancer, with responses lasting nearly 10 months.

Learn more 🔗: www.onclive.com/view/trastuz...

#gyncsm #gynonc
Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer | OncLive
Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.
www.onclive.com
April 11, 2026 at 6:09 PM
onclive.bsky.social
🧬 Mirvetuximab soravtansine + carboplatin demonstrated encouraging antitumor activity in platinum-sensitive ovarian cancer, supporting expansion of this ADC beyond the platinum-resistant setting. 📊
Read more ➡️ www.onclive.com/view/mirvetu... #gyncsm #oncology #SGOAM26
Mirvetuximab Soravtansine Plus Carboplatin Is Active in Platinum-Sensitive Ovarian Cancer | OncLive
Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.
www.onclive.com
April 13, 2026 at 9:27 PM
medpagetoday.com
A negative study in low-grade serous ovarian cancer might have uncovered a pathway toward more effective treatment for a large subgroup of patients, according to the NRG-GY019 trial. #SGOAM26
https://www.medpagetoday.com/meetingcoverage/sgo/120749
Chemo Combo Wins in Ovarian Cancer, But Single-Agent Therapy Still in the Game
NRG-GY019 backs current LGSOC standard care; endocrine therapy alone promising in some patients
www.medpagetoday.com
April 13, 2026 at 9:26 PM
onclive.bsky.social
🚨Breakthrough in platinum-resistant ovarian cancer 🚨: Final OS data from the phase 3 ROSELLA trial show relacorilant plus nab-paclitaxel cuts the risk of death by 35%.

Learn more 🔗: www.onclive.com/view/relacor...

#SGOAM26 @news.upmc.com #gyncsm #gynonc #medtwitter
Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer | OncLive
Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.
www.onclive.com
April 11, 2026 at 1:41 PM
onclive.bsky.social
💊 Promising data from #SGOAM26: Tisotumab vedotin + carboplatin + pembrolizumab ± bevacizumab delivered a 65.8% response rate and a median OS of 28 months in first-line recurrent/metastatic cervical cancer.

Learn more: 🔗 www.onclive.com/view/tisotum... #gyncsm #medtwitter #oncology
Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer | OncLive
Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.
www.onclive.com
April 13, 2026 at 9:18 PM
onclive.bsky.social
WATCH: Alexander Olawaiye, MD, of @upmchillmancc.bsky.social discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer. #ovca #gynsm #SGOAM26
www.onclive.com/view/dr-olaw...
Dr Olawaiye on the Final OS Data From the Phase 3 ROSELLA Trial in Platinum-Resistant Ovarian Cancer | OncLive
Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.
www.onclive.com
April 13, 2026 at 7:52 PM
onclive.bsky.social
🧬 Sofetabart mipitecan (LY4170156) demonstrated ~50% ORR and 78% disease control, with responses observed regardless of FRα expression and prior ADC exposure in early-phase data. 📊
Read more ➡️ www.onclive.com/view/sofetab...
#SGOAM26 #gyncsm
Sofetabart Mipitecan Displays Antitumor Activity in Recurrent Platinum-Resistant HGSOC | OncLive
Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.
www.onclive.com
April 13, 2026 at 2:40 PM
onclive.bsky.social
Ana Oaknin, MD, PhD, just gave an excellent presentation on the BEHOLD-1 study of mocertatug rezetecan in ovarian and endometrial cancers! Stay tuned to onclive.com for our full breakdown of the data. #SGOAM26 #gynsm #oncology
April 12, 2026 at 3:39 PM
onclive.bsky.social
🌴We are live on site at #SGOAM26 Stay tuned to onclive.com for all of our coverage of the meeting! #gynsm #Oncology
April 11, 2026 at 9:02 PM
onclive.bsky.social
🤝Individualized peer support significantly improved treatment completion among Black women, addressing a key driver of disparities in outcomes for this high-risk population. 📊
Read more ➡️ www.onclive.com/view/individ...
@uwmedicine.bsky.social #SGOAM26 #gynsm
#EndometrialCancer #Oncology
www.onclive.com
April 11, 2026 at 7:27 PM
onclive.bsky.social
⚠️ Letrozole monotherapy failed to demonstrate noninferiority vs letrozole + chemotherapy in advanced low-grade serous ovarian cancer—reinforcing the continued role of chemo in initial management. 📉
Read more ➡️ www.onclive.com/view/letrozo...
#SGOAM26 #ovca #gynsm
Letrozole Alone Fails to Demonstrate Noninferiority vs Letrozole/Chemo in Frontline, Advanced LGSOC | OncLive
Results from NRG-GY019 establish chemotherapy followed by letrozole as the definitive SOC for newly diagnosed stage II-IV low-grade serous ovarian carcinoma
www.onclive.com
April 11, 2026 at 5:30 PM
onclive.bsky.social
Abemaciclib plus letrozole was safe and active in advanced/recurrent endometrioid endometrial carcinoma.
#SGOAM26 #oncology
onclive.com/view/abemaci...
Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma | OncLive
Abemaciclib plus letrozole was safe and active in advanced/recurrent endometrioid endometrial carcinoma.
onclive.com
April 11, 2026 at 4:01 PM
medpagetoday.com
A novel regimen for platinum-resistant ovarian cancer solidified its role as a treatment option with a significant improvement in overall survival, according to a ROSELLA trial update. #SGOAM26
https://www.medpagetoday.com/meetingcoverage/sgo/120748
Novel Regimen Boosts Survival for Recurrent Platinum-Resistant Ovarian Cancer
Adding relacorilant to nab-paclitaxel improved median OS by 4 months
www.medpagetoday.com
April 13, 2026 at 6:28 PM
medpagetoday.com
As many as 70% of patients with advanced/metastatic HER2-expressing endometrial cancer responded to an investigational antibody-drug conjugate, according to phase II data. #SGOAM26
https://www.medpagetoday.com/meetingcoverage/sgo/120750
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug
Almost half of patients with recurrent/metastatic disease responded to trastuzumab pamirtecan
www.medpagetoday.com
April 13, 2026 at 1:49 PM
foundationmedicine.bsky.social
We’re heading to San Juan for #SGOAM26! Connect with the Foundation Medicine team to learn more about our high-quality genomic tests and services for gynecologic cancers at booth 112. Explore more: spkl.io/63325AFeWL
Foundation Medicine at SGO Annual Meeting on Women's Cancer, April 10-13, San Juan, PR.
April 2, 2026 at 4:00 PM
firstwordgroup.com
GSK readies pivotal trials for anti-B7-H4 ADC after promising early data #$GSK #SGOAM26 firstwordpharma.com/story/7178926
April 13, 2026 at 8:41 AM